

Background and aims We tested the hypothesis that moderate permissive hypercapnia (PHC) results in less lung injury than mild hypercapnia (MHC) and therefore may reduce the concentration of proinflammatory cytokines and acid sphingomyelinase (ASMase) in tracheal aspirates.

Methods Preterm infants (birthweight 400–1000 g, gestational age 23 0/7–28 6/7 weeks) requiring mechanical ventilation within the first 24 h after birth, were randomised to receive either PHC (PaCO₂ target area starting with 55–65 mm Hg at day 1 to 65–75 mm Hg at day 7) or MHC (PaCO₂ target area starting with 40–50 mm Hg at day 1 to 50–60 mm Hg at day 7). Tracheal aspirates were collected and analysed for IL-1 β , IL-6, IL-8, IL-10, MIP-1 α , LTB₄, TGF- β ₁, NPY, albumin, nitrate, ASMase and the secretory component for IgA. The primary endpoint BPD or death was determined at a postmenstrual age of 36 weeks \pm 1 day.

Results 71 infants were enrolled, 35 received PHC and 36 MHC. Analyses of variance for the main effect of the PaCO₂ targets did not detect significant differences: IL-1 β ($p = 0,42$), IL-6 ($p = 0,44$), IL-8 ($p = 0,91$), IL-10 ($p = 0,87$), MIP-1 α ($p = 0,34$), LTB₄ ($p = 0,87$), TGF- β ₁ ($p = 0,26$), NPY ($p = 0,47$), albumin ($p = 0,63$), nitrate ($p = 0,73$), ASMase ($p = 0,25$). BPD or death occurred in 9 (26%) and in 10 (28%) of infants receiving PHC or MHC.

Conclusion PHC did not result in lower inflammatory activity than MHC in ventilated ELBWI.

PS-203

PRE- AND POST-NCPAP VENTILATION PLASMA CYTOKINE LEVELS IN PRETERM NEWBORN INFANTS WITH EARLY RESPIRATORY DISTRESS

¹CG Carvalho, ¹RS Procianny, ²EC Neto, ¹RC Silveira. ¹Neonatology, HCPA-UFRGS, Porto Alegre - Brazil, Brazil; ²Neonatology, Laboratorio Nobel, Porto Alegre - Brazil, Brazil

10.1136/archdischild-2014-307384.501

Introduction Mechanical ventilation (MV) induces expression of pro-inflammatory cytokines. Early nasal continuous positive airway pressure (nCPAP) seems to prevent ventilator-induced lung injury – and these effects have not been studied in humans.

Objective To evaluate plasma levels IL-1 β , IL-6, IL-8, IL-10, and TNF- α immediately before the start of nCPAP and 2h later.

Methods Prospective cohort including preterm newborns with gestational age of 28–35 weeks admitted to a NICU for respiratory support. Newborns with malformations, congenital infections, sepsis, surfactant treatment, and receiving ventilatory support in the delivery room were excluded. Blood samples were collected right before and 2 h after the start of ventilation. Wilcoxon test was used for comparisons.

Results 23 preterm (mean weight 1850.65 \pm 403g; GA 32,36 \pm 1,74 weeks) were treated with nCPAP. A significant decrease in IL-6 levels was observed after 2 h of nCPAP. Of 15 newborns whose mothers received antenatal steroid, cytokine level was lower at the onset of nCPAP in all patients compared to those whose mothers didn't receive the treatment, but this effect was not sustained after 2 h.

Conclusion nCPAP was associated with minimal release of pro-inflammatory cytokines and seems to play a less harmful role, which was enhanced by the use of antenatal steroids. As MV usually promotes a significant inflammatory response, the use of nCPAP as initial protective respiratory strategy for preterm with moderate respiratory distress should be supported.

PS-204

THE UTILITY OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN ASSESSMENT OF RESPIRATORY DISTRESS IN TERM NEONATES

¹G Markovic-Sovtic, ²J Kosutic, ¹B Jankovic, ³A Sovtic, ⁴D Bojanin, ¹Z Rakonjac. ¹Department of Neonatology, Mother and Child Health Care Institute, Belgrade, Serbia; ²Department of Cardiology, Mother and Child Health Care Institute, Belgrade, Serbia; ³Department of Pulmonology, Mother and Child Health Care Institute, Belgrade, Serbia; ⁴Department of Laboratory Diagnostics, Mother and Child Health Care Institute, Belgrade, Serbia

10.1136/archdischild-2014-307384.502

Background and aims The N-terminal pro-brain natriuretic peptide (NTpro-BNP) is used to differentiate congestive heart failure and lung disease in children and adults. The aim of our study was to determine its utility in the assessment of respiratory distress (RD) in term neonates. We sought to find out whether it can distinguish cardiac from pulmonary aetiology of respiratory distress in term neonates.

Methods The NT pro-BNP level was determined in 60 neonates admitted for RD. They were further divided in two subgroups: 37 with congenital heart disease (CHD) and 23 with pulmonary disease. The control group consisted of 30 neonates with no signs of RD. Findings of auscultation, chest radiography, Silverman score and echocardiography were recorded for each patient. Blood samples for determining NT pro-BNP levels were obtained on admission, when blood sampling was indicated for the clinical management of the newborn.

Results The RD group, regardless of aetiology, showed significantly higher levels of NT-pro BNP than the control group ($p < 0.001$). Neonates with more severe RD had significantly higher level of NT-pro BNP ($p = 0.002$). No significant difference was found between neonates with RD due to CHD and those with RD due to pulmonary disease.

Conclusions Term neonates with RD have significantly higher NT-pro BNP levels than healthy neonates. Higher level of NTpro-BNP indicates more severe RD. A single measurement of NT pro-BNP level cannot be used as the sole biomarker for distinguishing between cardiogenic and noncardiogenic aetiology of RD in term neonates.

PS-205

INHALED NITRIC OXIDE INCREASES URINARY NITRIC OXIDE METABOLITES AND CGMP IN PREMATURE INFANTS: RELATIONSHIP TO PULMONARY OUTCOME

¹PL Ballard, ¹RL Keller, ²DM Black, ³DJ Durand, ³JD Merrill, ⁴EC Eichenwald, ⁵WE Truog, ⁶MC Mammel, ⁷R Steinhorn, ⁸R Ryan, ⁹SE Courtney, ¹RA Ballard. ¹Pediatrics, University of California San Francisco, San Francisco, USA; ²Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA; ³Pediatrics, Children's Hospital and Research Center, Oakland, USA; ⁴Pediatrics, University of Texas Medical School Houston, Houston, USA; ⁵Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, USA; ⁶Pediatrics, Children's Hospital and Clinics of Minnesota, St. Paul, USA; ⁷Pediatrics, University of California Davis Children's Hospital, Sacramento, USA; ⁸Pediatrics, Medical University of South Carolina, Charleston, USA; ⁹Pediatrics, University of Arkansas for Medical Sciences, Little Rock, USA

10.1136/archdischild-2014-307384.503

Background/aims Inhaled NO (iNO) has been tested for prevention of bronchopulmonary dysplasia in premature infants, however the role of cGMP is not known. We hypothesised that levels of NO metabolites (NOx) and cGMP in urine, as a non-invasive source for biospecimen collection, would reflect the dose of iNO and relate to pulmonary outcome.